Atopic Dermatitis Pipeline Analysis

Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology

According to DelveInsight, over 100 leading companies are actively involved in developing more than 110 treatment therapies for Atopic Dermatitis, reflecting a dynamic and expanding pipeline.

Atopic Dermatitis Overview:

Atopic dermatitis (AD), also called eczema, is a long-lasting inflammatory skin disorder that often appears in early childhood but can arise at any age. It manifests as itchy, red, and inflamed patches, with triggers that include genetic predisposition, an overactive immune response, infections, allergens, or irritants. Many individuals with moderate-to-severe AD also suffer from asthma, hay fever, or food allergies, making it the most common chronic skin disease in children.

The development of AD is driven by a complex interplay of factors: impaired skin barrier function, immune system imbalances, and environmental stresses. Mutations in the filaggrin gene worsen the condition by increasing water loss, altering skin pH, and causing dehydration, which weakens the barrier. A skewed balance between Th2 and Th1 cytokines contributes to immune dysregulation and heightened allergic responses. Additionally, spongiosis allows inflammatory signals to accumulate in the skin, and various dendritic cell populations—such as Langerhans cells and inflammatory dendritic epidermal cells—play key roles in driving the disease process.

Request for a detailed insights report on Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Atopic Dermatitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.

Key Takeaways from the Atopic Dermatitis Pipeline Report

• DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.

• In January 2025, Gilead Sciences partnered with Denmark’s LEO Pharma to develop treatments for inflammatory diseases, including atopic dermatitis. The collaboration involves Gilead gaining global rights to develop, manufacture, and commercialize the oral STAT6 program, which has shown potential in treating conditions like AD.

• December 2024 saw the FDA approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis in patients aged 12 and older who have not adequately responded to topical therapies. Nemolizumab is a subcutaneous monoclonal antibody targeting the interleukin-31 (IL-31) receptor, addressing itch and inflammation associated with AD.

• In December 2024, the FDA approved Vtama cream for atopic dermatitis in adults and children aged 2 years and older. This nonsteroidal topical treatment demonstrated significant reductions in itch and improved skin clearance in phase 3 trials.

• In September 2024, Organon announced an agreement to acquire Dermavant, aiming to expand its presence in the skin disorder treatment market. Dermavant’s Vtama cream, approved by the FDA in 2022 for psoriasis, was also under FDA review for treating atopic dermatitis, with a decision expected by the end of 2024.

• In September 2024, the FDA approved Eli Lilly’s injectable therapy, Ebglyss, for patients aged 12 and older with moderate-to-severe eczema unresponsive to other treatments. Ebglyss offers a once-monthly dosing regimen, targeting and neutralizing the IL-13 protein implicated in eczema progression.

• Key Atopic Dermatitis companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others are evaluating new drugs for Atopic Dermatitis to improve the treatment landscape.

• Promising Atopic Dermatitis pipeline therapies in various stages of development include Tapinarof, Etrasimod, B244, Lirentelimab, QY201, and others.

Atopic Dermatitis Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.

Download our free sample page report on Atopic Dermatitis pipeline insights

Atopic Dermatitis Emerging Drugs

• Tapinarof: Dermavant Sciences

• Etrasimod: Pfizer

• B244: AOBiome

• Lirentelimab: Allakos Inc.

• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Atopic Dermatitis Companies

More than 100 prominent companies are actively developing treatments for Atopic Dermatitis (AD). Among these, Dermavant Sciences has the most advanced drug candidate, currently in Phase III clinical trials.

DelveInsight’s report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Atopic Dermatitis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements

Atopic Dermatitis Pipeline Therapeutic Assessment

• Atopic Dermatitis Assessment by Product Type

• Atopic Dermatitis By Stage

• Atopic Dermatitis Assessment by Route of Administration

• Atopic Dermatitis Assessment by Molecule Type

Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Atopic Dermatitis Current Treatment Patterns

4. Atopic Dermatitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Atopic Dermatitis Late-Stage Products (Phase-III)

7. Atopic Dermatitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Atopic Dermatitis Discontinued Products

13. Atopic Dermatitis Product Profiles

14. Atopic Dermatitis Key Companies

15. Atopic Dermatitis Key Products

16. Dormant and Discontinued Products

17. Atopic Dermatitis Unmet Needs

18. Atopic Dermatitis Future Perspectives

19. Atopic Dermatitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Atopic Dermatitis Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/